Intuitive Surgical Earnings Call: Growth Surges, Margins Pinched

Intuitive Surgical ((ISRG)) has held its Q4 earnings call. Read on for the main highlights of the call.

Intuitive Surgical Balances Rapid Growth With Emerging Headwinds in Latest Earnings Call

Intuitive Surgical’s latest earnings call painted a picture of a company delivering strong growth and accelerating adoption of its robotic surgery platforms, while openly acknowledging a set of manageable but meaningful headwinds. Management highlighted double‑digit revenue and procedure expansion, robust cash generation, and rapid uptake of new systems like da Vinci 5 and Ion. At the same time, they flagged margin pressure from tariffs and product mix, rising operating expenses, and regional capital softness, particularly in China and Japan. Overall, the tone was confident and constructive, with leadership framing the current margin and capital challenges as near‑term issues against a backdrop of strong structural demand for robotic-assisted surgery.

Powerful Top-Line Performance With 21% Revenue Growth

Intuitive reported 2025 revenue of $10.1 billion, up 21% year over year, underscoring the breadth and durability of demand for its robotic platforms. Growth was driven by broad-based procedure adoption across specialties and geographies, with recurring revenue – primarily instruments, accessories, and services – playing an increasingly central role. The company’s scale is now such that continued high-teens to low‑20s revenue expansion translates into sizeable absolute dollar gains, strengthening its competitive position and reinforcing the recurring, “installed base plus usage” business model that investors typically prize.

Procedure Volumes Surge to Over 3.1 Million Patients

Procedure expansion remained the core engine of the business. In 2025, total procedures grew 19%, reaching more than 3.1 million patients treated with Intuitive’s systems. da Vinci procedures rose about 18%, with multiport procedures up 17% and single-port procedures surging 87%, reflecting strong demand for less invasive access approaches. Ion, Intuitive’s robotic bronchoscopy platform, posted a 51% procedure increase, demonstrating growing physician adoption in lung diagnostics and potential downstream oncology pathways. These volume gains improve utilization of the installed base and support the company’s high recurring revenue mix.

International Markets Accelerate, Now Over One-Third of Volume

Geographically, Intuitive showed particular strength outside the U.S., even as its home market continued to grow at a healthy pace. U.S. da Vinci procedures increased 15% to more than 2 million, confirming that penetration in American hospitals and surgery centers still has room to advance. International procedures grew even faster at 23%, reaching more than 1.1 million and accounting for roughly 35% of global procedures. This expanding OUS contribution diversifies the business and underscores the long runway for adoption in markets such as Europe and parts of Asia, though management did note specific capital and reimbursement challenges in certain countries.

System Placements Highlight Rapid Adoption of da Vinci 5

System placements remained strong in 2025, with 1,721 da Vinci systems placed during the year, including 870 units of the new da Vinci 5 platform, plus 107 SP systems and 195 Ion systems. In the fourth quarter alone, placements reached 532 systems, up 8% year over year, with 303 da Vinci 5 systems placed in the quarter. These numbers show a rapid shift towards the newest generation platform and continued demand for specialized systems like SP and Ion. While placements contribute to capital revenue in the near term, they more importantly expand the installed base that drives recurring revenue through ongoing procedure growth.

Installed Base Expansion and Utilization Improvements Support Recurring Revenue

The global installed base of da Vinci systems grew approximately 12% to just over 11,100 systems, a key indicator of Intuitive’s long-term revenue potential. Average global da Vinci utilization increased 3%, with multiport utilization up 3%, single-port utilization up 29%, and Ion utilization up 9%. The da Vinci 5 installed base reached roughly 1,232 systems since launch, signaling rapid penetration. Rising utilization on a growing installed base is strategically important because it amplifies instrument and accessory revenue per system, improving revenue visibility and providing a buffer against capital spending cycles.

Profitability Strengthens With Higher Margins and Cash Flow

Financially, Intuitive combined strong growth with expanding profitability and cash generation. Pro forma operating margin reached about 37%, improving roughly 70 basis points for the year despite incremental headwinds. Pro forma EPS increased 22%, outpacing revenue growth and reflecting operating leverage as scale expands. Free cash flow nearly doubled to $2.5 billion from $1.3 billion in 2024, giving the company significant flexibility to invest in R&D, capacity, and shareholder returns. This combination of growth, profitability, and cash generation remains a core part of the investment thesis.

Recurring Revenue Now Dominates the Business Model

Intuitive’s revenue mix continues to tilt toward recurring streams, bolstering stability. In the fourth quarter, recurring revenue grew 20% to $2.3 billion and represented 81% of total revenue. This high recurring proportion – driven by instruments, accessories, and services tied to procedure volumes – gives the company strong visibility into future cash flows and makes the business less dependent on lumpy system sales cycles. For investors, this mix helps support premium valuation multiples, provided procedure growth remains robust.

Single-Port and Ion Platforms Build Strategic Momentum

Single-port (SP) and Ion platforms were standouts in terms of growth and clinical traction. Single-port procedures grew 87% in 2025, while the SP installed base expanded 39% to 377 systems. The company secured multiple new clearances, broadening SP’s clinical use cases, including in areas like nipple-sparing mastectomy. Ion procedures grew 51% to about 144,000, with the installed base approaching roughly 1,000 systems and increasing 24%. These platforms deepen Intuitive’s presence in high‑value specialties and earlier diagnostic pathways, positioning the company for broader influence across the patient care continuum.

Capital Allocation: Aggressive Buybacks and a Fortress Balance Sheet

Intuitive leaned into share repurchases while maintaining a very strong balance sheet. The company bought back $2.3 billion of its own stock in 2025 at an average price of $478 per share, returning capital to shareholders and signaling confidence in its long-term outlook. Even after these buybacks, Intuitive ended the year with $9.0 billion in cash and investments, giving it substantial capacity for strategic acquisitions, internal investment, and continued buybacks. This financial strength provides a safety net amid macro and competitive uncertainty.

Product and Clinical Advancements Bolster Competitive Moat

On the innovation front, Intuitive continued to enhance its platforms and clinical credentials. The company received FDA clearance for several cardiac procedures on the da Vinci 5 (non‑Force Feedback) and is progressing the rollout of additional da Vinci 5 features, including Force Feedback instruments that aim to improve surgeon experience and precision. New SP 510(k) clearances – such as for nipple-sparing mastectomy – expand the platform’s procedural footprint. Meanwhile, published clinical studies highlighted reduced open conversion rates and favorable economic outcomes for robotic approaches, reinforcing the value proposition for hospitals and payers and strengthening Intuitive’s defense against emerging competitors.

Guidance Signals Solid Growth With Margin Headwinds

Looking to 2026, Intuitive guided da Vinci procedure growth to 13–15% year over year, indicating continued strong demand but a slight moderation from 2025’s pace. The company expects a pro forma gross profit margin of 67–68% of net revenue, which reflects a roughly 120‑basis‑point revenue impact from tariffs, up from about 65 bps in 2025. Pro forma operating expenses are forecast to grow 11–15%, and non‑cash stock‑based compensation is guided to $890–$920 million. Other income is expected at $355–$375 million, with a pro forma tax rate of 22–23%. Management noted that a higher mix of da Vinci 5 and XiR systems, more trade‑ins, and modest incremental depreciation from recent facility expansions will pressure margins, even as they refrain from giving specific capex guidance, saying spending is normalizing after recent investment cycles.

Tariffs and Product Mix Weigh on Gross Margins

Despite overall margin strength, the company is facing tangible gross margin pressure. Fourth-quarter pro forma gross margin fell to 67.8% from 69.5% a year ago, a decline of about 170 basis points. Management attributed roughly 95 basis points of the Q4 impact to tariffs, and they expect tariff effects of around 120 basis points of revenue in 2026. Beyond trade policy, a higher mix of newer, lower‑margin platforms such as da Vinci 5 and Ion, and increased service costs associated with da Vinci 5, also contributed to the margin compression. While these pressures reflect strategic growth investments, they temper near‑term profitability expansion.

Operating Expenses Rise on Donations, Hiring, and Facilities

Operating expenses climbed meaningfully, reflecting both one-time and structural cost increases. Pro forma operating expenses were up 16% in Q4, driven in part by a $70 million donation to the Intuitive Foundation. The company also added roughly 200 employees in the quarter, increased variable compensation, and incurred higher facility costs. For 2026, Intuitive expects operating expense growth of 11–15%, which suggests ongoing investment in R&D, commercial capabilities, and infrastructure. While investors may scrutinize the pace of spending, management appears intent on funding growth initiatives and ecosystem development that support long-term competitive advantage.

China Faces Intensifying Competition and Tender Pressures

China emerged as a notable weak spot in the quarter due to rising local competition and evolving tender dynamics. Provincial tenders are increasingly favoring local robotic surgery offerings, pressuring pricing and lowering win ratios for Intuitive’s systems. These factors contributed to reduced placements and weaker capital performance in China during Q4. While the underlying procedure opportunity remains substantial, the market is becoming more contested and policy-driven, suggesting that Intuitive may face a more volatile, price-sensitive environment in this strategically important region.

Japan Capital Constraints and Reimbursement Uncertainty

Japan also weighed on capital performance, with system placements coming in lower than expected as government budget constraints and delayed capital spending slowed purchases. In addition, upcoming reimbursement decisions expected in mid‑2026 could materially influence future procedure volumes. Reimbursement changes could either accelerate adoption if favorable or act as a drag if less supportive. Until the policy picture clarifies, investors should expect some uncertainty around the pace of growth in the Japanese market.

Ion Placements Dip as Focus Shifts to Utilization

While Ion procedure growth remained strong, capital placements for the platform declined in the fourth quarter. Ion system placements fell to 42 in Q4 from 69 a year earlier, a drop of roughly 39%. Management indicated that the emphasis has shifted toward driving higher utilization of the existing U.S. installed base rather than pushing aggressive new placements. This strategy may slow capital revenue in the near term but aims to solidify procedure usage and economics before the next wave of expansion, an approach that could pay off in more sustainable adoption over time.

ASP Pressure From Refurbished and Lower-Priced Systems

Average selling prices for systems are coming under pressure as Intuitive broadens its product offering across price points. The company is expanding the mix of refurbished XiR systems, which carry lower ASPs than new Xi units, and expects a higher proportion of XiR and trade-ins in the overall mix. This strategy can help address more cost-conscious customers and extend the lifecycle of the installed ecosystem, but it also weighs on capital revenue per unit. The trade‑off is a more accessible product range in exchange for some near-term ASP compression.

New Platforms and Service Costs Add to Margin Headwinds

Intuitive’s shift toward its newer platforms is strategically important but creates transitional cost friction. The greater contribution from da Vinci 5 and Ion – both currently carrying lower margins – combined with elevated service costs tied to da Vinci 5 deployment, has pressured gross margin despite ongoing product cost reductions. Management framed these impacts as part of the normal evolution of a product cycle, where early years of a new platform require higher investment. Over time, scaling production, service efficiencies, and maturing the installed base could help recapture some of the lost margin.

In sum, Intuitive Surgical’s earnings call showcased a company delivering powerful growth in revenue, procedures, and cash flow, underpinned by rapid adoption of new robotic platforms and expanding global reach. While tariffs, product mix, operating expense growth, and regional capital challenges in China and Japan are compressing margins and adding complexity to capital trends, management portrayed these as manageable headwinds amid strong structural demand for robotic-assisted surgery. For investors, the story remains one of high-quality growth with some near-term margin and regional volatility, anchored by a large and increasingly utilized installed base and a product portfolio that continues to advance clinically and competitively.